Differentiation therapies in human cancers

doi:10.3760/cma.j.cn371439-20231013-00016

Abstract

Abstract:

Cancer phenotypic plasticity includes dedifferentiation，blocked differentiation and trans- differentiation，and differentiation therapy targeting tumor cell plasticity is becoming a new therapeutic model for human cancers. The application of inducing differentiation，initiating differentiation and regulating differentiation in tumor differentiation therapy will promote the directed differentiation of tumor cells into mature cells and the remodeling of phenotypes，thus to achieve the purpose of cancer treatment.

Key words: Neoplasms, Cell differentiation, Drug therapy

Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.

Figures/Tables 1

References 45

[1]	Pérez-González A. Bévant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy[J]. Nat Cancer, 2023, 4(8): 1063-1082. DOI: 10.1038/s43018-023-00595-y.
[2]	Yuan S, Norgard RJ, Stanger BZ. Cellular plasticity in cancer[J]. Cancer Discov, 2019, 9(7): 837-851. DOI: 10.1158/2159-8290.CD-19-0015. pmid: 30992279
[3]	Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46. DOI: 10.1158/2159-8290.CD-21-1059. pmid: 35022204
[4]	de Thé H. Differentiation therapy revisited[J]. Nat Rev Cancer, 2018, 18(2): 117-127. DOI: 10.1038/nrc.2017.103. pmid: 29192213
[5]	Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer[J]. Nature, 2009, 457(7229): 608-611. DOI: 10.1038/nature07602.
[6]	Belote RL, Le D, Maynard A, et al. Human melanocyte development and melanoma dedifferentiation at single-cell resolution[J]. Nat Cell Biol, 2021, 23(9): 1035-1047. DOI: 10.1038/s41556-021-00740-8. pmid: 34475532
[7]	Kozono S, Lin YM, Seo HS, et al. Arsenic targets Pin1 and coope-rates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells[J]. Nat Commun, 2018, 9(1): 3069. DOI: 10.1038/s41467-018-05402-2.
[8]	Davalos V, Esteller M. Cancer epigenetics in clinical practice[J]. CA Cancer J Clin, 2023, 73(4): 376-424. DOI: 10.3322/caac.21765.
[9]	Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer[J]. Science, 2023, 379(6632): eaaw3835. DOI: 10.1126/science.aaw3835.
[10]	Ferrarelli LK. Exploiting an epigenetic Switch in adrenal cancer[J]. Sci Signal, 2023, 16(794): 10. DOI: 10.1126/scisignal.adj7203.
[11]	Xie J, Wang Z, Fan W, et al. Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma[J]. Signal Transduct Target Ther, 2021, 6(1): 333. DOI: 10.1038/s41392-021-00702-4.
[12]	Anastas JN, Zee BM, Kalin JH, et al. Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG[J]. Cancer Cell, 2019, 36(5): 528-544.e10. DOI: 10.1016/j.ccell.2019.09.005. pmid: 31631026
[13]	Ianniciello A, Zarou MM, Rattigan KM, et al. ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy[J]. Sci Transl Med, 2021, 13(613): eabd5016. DOI: 10.1126/scitranslmed.abd5016.
[14]	Tan SH, Barker N. Stemming colorectal cancer growth and metastasis: HOXA5 forces cancer stem cells to differentiate[J]. Cancer Cell, 2015, 28(6): 683-685. DOI: 10.1016/j.ccell.2015.11.004. pmid: 26678334
[15]	Zhan TZ, Ambrosi G, Wandmacher AM, et al. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer[J]. Nat Commun, 2019, 10(1): 2197. DOI: 10.1038/s41467-019-09898-0.
[16]	Fang XG, Huang Z, Zhai K, et al. Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice[J]. Sci Transl Med, 2021, 13(600): eabc7275. DOI: 10.1126/scitranslmed.abc7275.
[17]	Kemeny LV, Fisher DE. Targeting the (Un)differentiated State of Cancer[J]. Cancer Cell, 2018, 33(5): 793-795. DOI: 10.1016/j.ccell.2018.04.007. pmid: 29763619
[18]	Malta TM, Sokolov A, Gentles AJ, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation[J]. Cell, 2018, 173(2): 338-354.e15. DOI: 10.1016/j.cell.2018.03.034. pmid: 29625051
[19]	Saha SK, Parachoniak CA, Ghanta KS, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer[J]. Nature, 2014, 513(7516): 110-114. DOI: 10.1038/nature13441.
[20]	Molenaar RJ, Wilmink JW. IDH1/2 mutations in cancer stem cells and their implications for differentiation therapy[J]. J Histochem Cytochem, 2022, 70(1): 83-97. DOI: 10.1369/00221554211062499. pmid: 34967233
[21]	Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma[J]. N Engl J Med, 2023, 389(7): 589-601. DOI: 10.1056/NEJMoa2304194.
[22]	Morris JP 4th, Yashinskie JJ, Koche R, et al. α-Ketoglutarate links p53 to cell fate during tumour suppression[J]. Nature, 2019, 573(7775): 595-599. DOI: 10.1038/s41586-019-1577-5.
[23]	Tran TQ, Hanse EA, Habowski AN, et al. α-Ketoglutarate atte-nuates Wnt signaling and drives differentiation in colorectal cancer[J]. Nat Cancer, 2020, 1(3): 345-358. DOI: 10.1038/s43018-020-0035-5.
[24]	Kaufman CK, Mosimann C, Fan ZP, et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation[J]. Science, 2016, 351(6272): aad2197. DOI: 10.1126/science.aad2197.
[25]	Capparelli C, Purwin TJ, Glasheen M, et al. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma[J]. Nat Commun, 2022, 13(1): 1381. DOI: 10.1038/s41467-022-28801-y. pmid: 35296667
[26]	Henning AN, Klebanoff CA, Restifo NP. Silencing stemness in T cell differentiation[J]. Science, 2018, 359(6372): 163-164. DOI: 10.1126/science.aar5541. pmid: 29326263
[27]	Gill AL, Wang PH, Lee J, et al. PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors[J]. Sci Immunol, 2023, 8(86): eadg0539. DOI: 10.1126/sciimmunol.adg0539.
[28]	Castiglioni A, Yang Y, Williams K, et al. Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors[J]. Nat Commun, 2023, 14(1): 4703. DOI: 10.1038/s41467-023-40398-4. pmid: 37543621
[29]	Collins SM, Alexander KA, Lundh S, et al. TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells[J]. Sci Adv, 2023, 9(29): eadh2605. DOI: 10.1126/sciadv.adh2605.
[30]	Burdziak C, Alonso-Curbelo D, Walle T, et al. Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumori-genesis[J]. Science, 2023, 380(6645): eadd5327. DOI: 10.1126/science.add5327.
[31]	Rüland L, Andreatta F, Massalini S, et al. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss[J]. Nat Commun, 2023, 14(1): 2377. DOI: 10.1038/s41467-023-37951-6. pmid: 37137901
[32]	Kim MR, Wu MJ, Zhang YS, et al. TET2 directs mammary luminal cell differentiation and endocrine response[J]. Nat Commun, 2020, 11(1): 4642. DOI: 10.1038/s41467-020-18129-w. pmid: 32934200
[33]	Quintanal-Villalonga A, Durani V, Sabet A, et al. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers[J]. Sci Transl Med, 2023, 15(707): eadf7006. DOI: 10.1126/scitranslmed.adf7006.
[34]	Duplaquet L, Li Y, Booker M, et al. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer[J]. Nat Cell Biol, 2023, 25(9): 1346-1358. DOI: 10.1038/s41556-023-01210-z. pmid: 37591951
[35]	Chen HY, Durmaz YT, Li Y, et al. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1[J]. Nat Commun, 2022, 13(1): 4998. DOI: 10.1038/s41467-022-31998-7.
[36]	Deshors P, Arnauduc F, Boëlle B, et al. Impact of regorafenib on endothelial transdifferentiation of glioblastoma stem-like cells[J]. Cancers (Basel), 2022, 14(6): 1551. DOI: 10.3390/cancers14061551.
[37]	Chan JM, Zaidi S, Love JR, et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling[J]. Science, 2022, 377(6611): 1180-1191. DOI: 10.1126/science.abn0478.
[38]	Liu J, Wang X, Chen AT, et al. ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage[J]. Nat Commun, 2022, 13(1): 2196. DOI: 10.1038/s41467-022-29884-3.
[39]	Bala P, Rennhack JP, Aitymbayev D, et al. Aberrant cell state plasticity mediated by developmental reprogramming precedes colorectal cancer initiation[J]. Sci Adv, 2023, 9(13): eadf0927. DOI: 10.1126/sciadv.adf0927.
[40]	Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy[J]. Nat Rev Drug Discov, 2020, 19(1): 39-56. DOI: 10.1038/s41573-019-0044-1. pmid: 31601994
[41]	Schmitt CA, Wang B, Demaria M. Senescence and cancer-role and therapeutic opportunities[J]. Nat Rev Clin Oncol, 2022, 19(10): 619-636. DOI: 10.1038/s41571-022-00668-4.
[42]	Wang TW, Johmura Y, Suzuki N, et al. Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes[J]. Nature, 2022, 611(7935): 358-364. DOI: 10.1038/s41586-022-05388-4.
[43]	张百红, 岳红云. 肿瘤休眠的周期和意义[J]. 现代肿瘤医学, 2023, 31(2): 392-394. DOI: 10.3969/j.issn.1672-4992.2023.02.039.
[44]	Shen S, Vagner S, Robert C. Persistent cancer cells: the deadly survivors[J]. Cell, 2020, 183(4): 860-874. DOI: 10.1016/j.cell.2020.10.027. pmid: 33186528
[45]	Lyko F. Distal memory in wound healing and cancer[J]. Nat Cell Biol, 2023, 25(5): 631-632. DOI: 10.1038/s41556-023-01132-w. pmid: 37081166

细胞可塑	作用机制	药物类型	临床试验
诱导分化	表观遗传剂	EZH2抑制剂，HDAC抑制剂	临床前研究^[10⇓-12]
	自噬诱导剂	ULK1抑制剂	临床前研究^[13]
	干性调节剂	SOX2抑制剂，Wnt抑制剂，MEK抑制剂，erastin	临床前研究^[15⇓-17]
启动分化	代谢调节剂	Vorasidenib	Ⅱ期^[20-21]
	转录因子调节剂	SOX10拮抗剂	临床前研究^[25]
	免疫细胞分化剂	抗PD-1/PD-L1抗体	临床应用^[27-28]
调控分化	染色质可塑剂	Exportin1抑制剂，LSD1抑制剂	临床前研究^[33⇓-35]
	血管生成抑制剂	瑞格非尼	临床应用^[36]
	生长信号阻断剂	ZNF117	临床前研究^[38]
	衰老细胞清除剂	抗PD-1/PD-L1抗体	临床应用^[42]